ASCO Expands TAPUR Sites; Inks Collaborations to Investigate Precision Oncology Globally

Jun 04, 2017

|

CHICAGO (GenomeWeb) – The American Society of Clinical Oncology has expanded the Targeted Agent and Profiling Utilization Registry (TAPUR) study to around 100 sites in the US, and inked collaborations that will also bolster other countries' ability to explore precision oncology hypotheses.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

ASCO Expands TAPUR Sites; Inks Collaborations to Investigate Precision Oncology Globally

To read the full story....

Breaking News

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

BeiGene, Zymeworks Dose First Patient in Phase IB/II Trial for HER2-Positive Cancers

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

OSE Immunotherapeutics Meets Primary Endpoint in Phase III Trial for HLA-A2 Positive Lung Cancer

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Featured White Papers

What's Popular?

Metastatic Prostate Cancer Features Linked to Immunotherapy Response, Despite Low TMB

Full BRCA1 Gene Deletion Suspected to Contribute to Patient's Long PARP Inhibitor Response

Mutations in PTEN, ESR1 Promote Piqray Resistance in HR-Positive Breast Cancer, Study Finds

Pancreatic Cancers With TP53 Mutations More Sensitive to Adjuvant Chemo, Study Shows

VBL Therapeutics, NanoCarrier to Expand Clinical Trial of Ovarian Cancer Drug to Japan

Sponsorships